Physician profile
Carson Moseley
NPI 1861997066
$4,600.98
in general payments reported to CMS, 2019-2025
7 companies · $3,687 in 2025
The $3,687 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $179 · 2024: $735 · 2025: $3,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,251 · Food and Beverage: $1,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,251.00 |
| Food and Beverage | $1,349.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,405.08 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $307.09 | 2024-2025 | |
| Celgene Corporation | $292.09 | 2023-2024 | Zeposia |
| Ucb, INC. | $222.12 | 2023-2025 | Rystiggo |
| Alexion Pharmaceuticals, INC. | $212.80 | 2024-2025 | Ultomiris |
| Emd Serono, INC. | $129.79 | 2024 | |
| Genentech USA, INC. | $32.01 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carson Moseley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.